Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death

被引:86
作者
Dutton, A
O'Neil, JD
Milner, AE
Reynolds, GM
Starczynski, J
Crocker, J
Young, LS
Murray, PG [1 ]
机构
[1] Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Div Canc Studies,Dept Pathol, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Liver Res Labs, Birmingham B15 2TT, W Midlands, England
[3] Birmingham Heartlands Hosp, Dept Cellular Pathol, Birmingham B15 2TT, W Midlands, England
关键词
Fas ligand; apoptosis; small interfering RNA;
D O I
10.1073/pnas.0400765101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hodgkin's lymphoma (HQ is characterized by the presence of malignant so-called Hodgkin's/Reed-Sternberg (HIRS) cells, which display resistance to certain apoptotic stimuli, including a lack of sensitivity to Fas-mediated cell death. However, the mechanisms responsible for their resistance to apoptosis inducers have not been elucidated. Here we confirm that both HL-derived cell lines and the HIRS cells of primary HL tissues express Fas ligand (FasL) along with the inhibitory c-FLIP protein. Down-regulation of cellular FLICE (FADD-like IL-1beta-converting enzyme)-inhibitory protein (c-FLIP) through the use of specific small inhibitory RNAs (siRNAS) leads to reduced viability of the L428 and L591 HIL-clerived cell lines. To determine whether enclogenous FasL was responsible for the reduction in cell viability observed after down-regulation of c-FLIP, L428 and L591 cells were treated with c-FLIP-specific siRNAs with and without siRNAs directed to FasL. Treatment of these cells with both c-FLIP- and FasL-specific siRNAs in combination restored cell viability to near control levels. Our results provide a mechanism whereby IHRS cells are protected from autonomous FasL-mediated cell death while preserving their ability to evade immunosurveillance. Targeting c-FLIP could provide a novel approach to the treatment of HL.
引用
收藏
页码:6611 / 6616
页数:6
相关论文
共 34 条
  • [1] Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
    Bargou, RC
    Emmerich, F
    Krappmann, D
    Bommert, K
    Mapara, MY
    Arnold, W
    Royer, HD
    Grinstein, E
    Greiner, A
    Scheidereit, C
    Dörken, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) : 2961 - 2969
  • [2] High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells
    Bargou, RC
    Leng, C
    Krappmann, D
    Emmerich, F
    Mapara, MY
    Bommert, K
    Royer, HD
    Scheidereit, C
    Dorken, B
    [J]. BLOOD, 1996, 87 (10) : 4340 - 4347
  • [3] EXPRESSION OF FUNCTIONAL CD30 ANTIGEN ON REED-STERNBERG CELLS AND HODGKINS-DISEASE CELL-LINES
    CARBONE, A
    GLOGHINI, A
    GATTEI, V
    ALDINUCCI, D
    DEGAN, M
    DEPAOLI, P
    ZAGONEL, V
    PINTO, A
    [J]. BLOOD, 1995, 85 (03) : 780 - 789
  • [4] DIEHL V, 1982, CANCER TREAT REP, V66, P615
  • [5] GRUSS HJ, 1994, BLOOD, V84, P2305
  • [6] FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis
    Hennino, A
    Bérard, M
    Krammer, PH
    Defrance, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (04) : 447 - 458
  • [7] Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells
    Hennino, A
    Berard, M
    Casamayor-Pallejà, M
    Krammer, PH
    Defrance, T
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (06) : 3023 - 3030
  • [8] Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model
    Imanishi, T
    McBride, J
    Ho, Q
    O'Brien, KD
    Schwartz, SM
    Han, DKM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (01) : 125 - 137
  • [9] KAMESAKI H, 1986, BLOOD, V68, P285
  • [10] Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
    Kanzler, H
    Kuppers, R
    Hansmann, ML
    Rajewsky, K
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) : 1495 - 1505